Arcus Biosciences, Inc.

NYSE:RCUS Stock Report

Market Cap: US$3.1b

Arcus Biosciences Management

Management criteria checks 2/4

Arcus Biosciences' CEO is Terry Rosen, appointed in May 2015, has a tenure of 10.92 years. total yearly compensation is $9.66M, comprised of 8% salary and 92% bonuses, including company stock and options. directly owns 2.06% of the company’s shares, worth $64.24M. The average tenure of the management team and the board of directors is 5.5 years and 6.1 years respectively.

Key information

Terry Rosen

Chief executive officer

US$9.7m

Total compensation

CEO salary percentage8.03%
CEO tenure10.9yrs
CEO ownership2.1%
Management average tenure5.5yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now

Apr 27

RCUS: Future Upside Will Be Driven By Kidney Cancer Trial Progress

Analysts have lifted their price targets on Arcus Biosciences into the low to mid $40s, citing updated expectations around profitability, refreshed discount rate assumptions, and relative P/E comparisons. These factors feed into a new fair value estimate of $34.20 per share.

RCUS: Future Upside Will Be Anchored By Renal Cancer Trial Progress

Analysts have raised the fair value estimate for Arcus Biosciences to $34.20 from $32.30, reflecting recent price target increases into the $28 to $45 range and renewed focus on casdatifan and the broader oncology pipeline. Analyst Commentary Recent Street research on Arcus Biosciences shows a mix of optimism around casdatifan and the oncology pipeline, along with caution about execution timing and risk and reward at current share levels.

RCUS: Late Stage Kidney Cancer Trial Results Will Drive Bullish Repricing Outlook

Narrative Update on Arcus Biosciences Analysts have nudged their average price target on Arcus Biosciences higher, with recent moves such as Citi lifting its target to $45 and Goldman Sachs raising its target to $28 from $16. These revisions reflect updated views on casdatifan trial data and the potential contribution of additional oncology programs.

RCUS: Late Stage Kidney Cancer Data Will Shape Repricing Outlook

Narrative Update The updated analyst price target for Arcus Biosciences moves to $49.00 from $47.00, as analysts factor in higher modeled revenue growth, adjust discount rates, and reflect a slightly higher future P/E multiple informed by recent target changes and mixed rating actions across the Street. Analyst Commentary Recent Street research on Arcus Biosciences presents a mixed but constructive backdrop, with several bullish analysts highlighting upside potential alongside more cautious views that focus on risk and timing.

RCUS: Future Upside Will Be Driven By Renal Cancer Data Milestones

Narrative Update: Arcus Biosciences The analyst price target for Arcus Biosciences has been adjusted slightly lower to $32.30 from $33.00, as analysts weigh recent upgrades and downgrades that highlight both the potential of casdatifan in renal cell carcinoma and a more balanced risk and reward profile at current levels. Analyst Commentary Recent Street research on Arcus Biosciences reflects a mix of optimism around casdatifan and caution around timing, risk and current valuation, which together help explain the modest trim in the overall price target.

RCUS: Kidney Cancer Focus And Limited 2026 Updates Will Shape Share Performance

Narrative update: Arcus Biosciences The analyst price target for Arcus Biosciences has increased from US$16 to US$20. Analysts cite updated views on casdatifan's potential in renal cell carcinoma (a US$1.7b risk-adjusted opportunity), as well as differing opinions on near-term news flow and the overall risk-reward profile.

RCUS: Future Upside Will Be Driven By 12 Month Efficacy Advantage

Analysts have modestly trimmed their fair value estimate for Arcus Biosciences to US$33.00 per share. This reflects updated assumptions on slower revenue growth, a slightly higher discount rate, and stronger projected margins and P/E multiples supported by recent casdatifan data and mixed, but generally constructive, Street research.

RCUS: Future Dependence On Single Late Line Kidney Cancer Program Will Pressure Shares

Analysts have trimmed their consolidated price target on Arcus Biosciences by a few dollars to around the low US$20s. This reflects a more balanced risk and reward profile as expectations for casdatifan moderate and valuation assumptions, including future P/E, are reset closer to recent Street research.

RCUS: Future Reliance On Single Oncology Asset Will Increase Downside Risk

Analysts have raised their fair value estimate for Arcus Biosciences from $12.00 to $16.00 per share, citing stronger than expected casdatifan efficacy data. They believe this supports higher long term profitability and justifies a richer future earnings multiple, even with more conservative revenue growth assumptions.

RCUS: Future Upside Will Be Driven By 12 Month Progression-Free Advantage

Analysts have nudged their price target on Arcus Biosciences higher by approximately $1 per share, citing stronger than expected casdatifan efficacy data, including progression free survival and response rates that appear to outpace competing therapies. Analyst Commentary Bullish analysts highlight that the latest casdatifan data meaningfully improves the risk reward profile for Arcus, supporting higher valuation multiples as investors gain confidence in the durability and competitiveness of the asset.

RCUS: Future Gains Will Be Driven by 12 Month Survival Advantage

Arcus Biosciences' analyst price target has increased from $30.20 to $32.22, as analysts highlight encouraging data for casdatifan that underline its competitive potential and support the upward revision. Analyst Commentary Following the latest clinical updates for casdatifan, analysts have offered a mix of optimism and caution regarding Arcus Biosciences' outlook.

RCUS: Future Gains Will Be Driven by Superior Efficacy in Renal Cancer

Analysts have modestly lowered their fair value estimate for Arcus Biosciences from $31.27 to $30.20 per share. They cite encouraging clinical data on casdatifan while also factoring in updated financial assumptions and recent analyst projections for the company's future performance.

Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported, And Analysts Assigned A US$29.60 Price Target

Nov 01
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported, And Analysts Assigned A US$29.60 Price Target

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Fly 45% But Investors Aren't Buying For Growth

Oct 28
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Fly 45% But Investors Aren't Buying For Growth

Analyst Sentiment Improves on Arcus Biosciences as Price Targets Rise with Strong Trial Data

Analysts have raised their price target for Arcus Biosciences from $29.91 to $31.27. They cite encouraging new trial data and improved revenue growth forecasts as key drivers supporting the higher valuation.

Phase 3 Trials Will Shape Casdatifan Prospects Despite Regulatory Hurdles

Arcus Biosciences’ analyst price target has been raised from $28.36 to $29.91 per share, as analysts cite promising updated trial results for Casdatifan. These results are supporting an increased company valuation.

There's No Escaping Arcus Biosciences, Inc.'s (NYSE:RCUS) Muted Revenues Despite A 28% Share Price Rise

Sep 06
There's No Escaping Arcus Biosciences, Inc.'s (NYSE:RCUS) Muted Revenues Despite A 28% Share Price Rise

Does Arcus Biosciences (NYSE:RCUS) Have A Healthy Balance Sheet?

Jul 10
Does Arcus Biosciences (NYSE:RCUS) Have A Healthy Balance Sheet?

Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17%

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry

May 04
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry
User avatar

Phase 3 Trials Will Shape Casdatifan Prospects Despite Regulatory Hurdles

Arcus Biosciences is focusing on casdatifan's late-stage development, promising significant differentiation and competitive advantage in the RCC market.

Little Excitement Around Arcus Biosciences, Inc.'s (NYSE:RCUS) Revenues As Shares Take 26% Pounding

Mar 06
Little Excitement Around Arcus Biosciences, Inc.'s (NYSE:RCUS) Revenues As Shares Take 26% Pounding

Is Arcus Biosciences (NYSE:RCUS) A Risky Investment?

Feb 10
Is Arcus Biosciences (NYSE:RCUS) A Risky Investment?

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Jan 13

Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS)

Dec 12
Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS)

Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking

Nov 21
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking

Arcus Biosciences: Advancing On Several Fronts

Oct 29

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Sep 23

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15
Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

CEO Compensation Analysis

How has Terry Rosen's remuneration changed compared to Arcus Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$10mUS$775k

-US$353m

Sep 30 2025n/an/a

-US$341m

Jun 30 2025n/an/a

-US$298m

Mar 31 2025n/an/a

-US$391m

Dec 31 2024US$7mUS$725k

-US$283m

Sep 30 2024n/an/a

-US$270m

Jun 30 2024n/an/a

-US$249m

Mar 31 2024n/an/a

-US$231m

Dec 31 2023US$10mUS$650k

-US$307m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$287m

Mar 31 2023n/an/a

-US$279m

Dec 31 2022US$9mUS$350k

-US$267m

Sep 30 2022n/an/a

US$80m

Jun 30 2022n/an/a

US$67m

Mar 31 2022n/an/a

US$58m

Dec 31 2021US$9mUS$367k

US$53m

Sep 30 2021n/an/a

-US$278m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$168m

Dec 31 2020US$6mUS$326k

-US$123m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$112m

Mar 31 2020n/an/a

-US$95m

Dec 31 2019US$2mUS$340k

-US$85m

Compensation vs Market: Terry's total compensation ($USD9.66M) is above average for companies of similar size in the US market ($USD7.00M).

Compensation vs Earnings: Terry's compensation has increased whilst the company is unprofitable.

CEO

Terry Rosen (65 yo)

10.9yrs
Tenure
US$9,656,813
Compensation

Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. and Epiodyne, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has be...

Leadership Team

NamePositionTenureCompensationOwnership
Terry Rosen
Co-Founder10.9yrsUS$9.66m2.06%
$ 64.2m
Juan Jaen
Co- Founder & President10.9yrsUS$3.52m0.88%
$ 27.3m
Robert Goeltz
Principal Financial Officer & CFO5.7yrsUS$2.67m0.016%
$ 512.8k
Jennifer Jarrett
Advisorless than a yearUS$3.52m0.099%
$ 3.1m
Richard Markus
Chief Medical Officer1.3yrsUS$4.51m0.0074%
$ 229.3k
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Alexander Azoy
Chief Accounting Officer3.1yrsno data0.015%
$ 459.5k
Jonathan Yingling
Chief Scientific Officer5.3yrsno datano data
Pia Eaves
Vice President of Investor Relations & Strategyno datano datano data
Carolyn Tang
General Counsel & Corporate Secretary7.7yrsUS$2.92m0.060%
$ 1.9m
Holli Kolkey
Vice President of Corporate Communicationsno datano datano data
Yvonne Gehring
Senior Vice President of Human Resourcesno datano datano data
5.5yrs
Average Tenure
54yo
Average Age

Experienced Management: RCUS's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Terry Rosen
Co-Founder11yrsUS$9.66m2.06%
$ 64.2m
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Yasunori Kaneko
Lead Independent Director10.9yrsUS$500.33k0.14%
$ 4.5m
Kathryn Falberg
Independent Director8.6yrsUS$468.83k0.13%
$ 3.9m
Andrew Perlman
Independent Director5.3yrsUS$472.54k0.023%
$ 727.2k
Jeffrey Bluestone
Chairman of Scientific Advisory Boardno datano data0%
$ 0
C. Machado
Independent Director6.3yrsUS$455.04k0.020%
$ 627.5k
David Lacey
Independent Director & Member of Scientific Advisory Board5.9yrsUS$563.76k0.046%
$ 1.4m
Linda Higgins
Member of Scientific Advisory Board & Director4.7yrsno datano data
Antoni Ribas
Independent Director & Member of Scientific Advisory Board11.3yrsUS$521.26k0.031%
$ 964.9k
Nicole Lambert
Independent Director4.7yrsUS$461.25k0.019%
$ 595.1k
Stefani Spranger
Member of Scientific Advisory Board5.6yrsno datano data
6.1yrs
Average Tenure
64.5yo
Average Age

Experienced Board: RCUS's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/29 07:02
End of Day Share Price 2026/04/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcus Biosciences, Inc. is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Jason ZemanskyBofA Global Research
Li Wang WatsekCantor Fitzgerald & Co.